

BUILDING YOUR PATH TO JAPAN AND ASIA, TOGETHER

Guiding Biotechs Through Japan's
Changing Pharmaceutical
Development Landscape

Noriyuki Takai
President and CEO



Tatsuya Koishi
Senior Executive Officer



SESSION OVERVIEW

*Discover how EPS BIOPath helps biotech innovators
succeed in Japan by:*

1. Accelerating Market Entry into Japan and Asia

*Learn practical strategies for PMDA engagement and
market entry into Japan and Asia*

2. Japan's Evolving Regulatory Landscape

*Gain key insights in Japan, including MRCTs, the use
of global clinical data, and expedited pathways*

3. From Strategy to Execution

*Discover how EPS supports emerging biotech
companies from strategy to clinical execution and
submission*

Rumi Kawasaki
Executive Officer



Motoki Fujii
Executive Professional,
Regulatory Affairs



Rie Yamazaki
Manager,
Project Management



Ariko Machiyama
Professional,
Project Management



BUILDING YOUR PATH TO JAPAN AND ASIA, TOGETHER


What is EPS BioPath?

Key Considerations for Japan/Asia Market Entry



- Understanding local development requirements
- Optimizing regional study strategies
- Navigating regulatory expectations
- Aligning strategy with execution

Our Sponsor-Centric approach



What You Gain



- ✓ Minimize time and cost
- ✓ Avoid redundant studies
- ✓ Maximize use of global data
- ✓ Accelerate your plan to Japan & Asia

Why EPS?



Integrated CRO Platform

Clinical, regulatory, CMC, data science, and post marketing



Strong Local Network

Deep regulatory expertise and relationships



Proven Experience

Supporting global biotech companies across development stages



Sponsor-Centric Approach

We stand in your shoes and flexibly tailor support to your development stage

SEMINAR REGISTRATION



[REGISTER HERE](#)

CONTACT EPS



prj-sd@eps.co.jp



<https://www.epsi-global.com>

VISIT US AT BOOTH D-72